Abstract
Alzheimers disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid β-peptide (Aβ). All converging lines of evidence suggest that progressive accumulation of the Aβ plays a central role in the genesis of Alzheimers disease and it was long understood that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Aβ fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Aβ fibrils formation and depolymerizate Aβ fibrils also. Over the past decade, data have emerged from the use of several sources of Aβ (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Aβ oligomers are also injurious. Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, β-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Aβ revealed a significant dose-dependent decrease in the levels of cytosolic β-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Aβ, therefore the activation of Wnt signaling protects agains the Aβ neurotoxicity. Here we review recent progress about Aβ structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Aβ oligomers.
Keywords: Alzheimer's disease, senile plaque, amyloid β-peptide, neurodegeneration, synaptic toxicity, amyloid oligomers, acetylcholinesterase, Wnt-signaling pathway
Current Alzheimer Research
Title: Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Volume: 5 Issue: 3
Author(s): Waldo Cerpa, Margarita C. Dinamarca and Nibaldo C. Inestrosa
Affiliation:
Keywords: Alzheimer's disease, senile plaque, amyloid β-peptide, neurodegeneration, synaptic toxicity, amyloid oligomers, acetylcholinesterase, Wnt-signaling pathway
Abstract: Alzheimers disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid β-peptide (Aβ). All converging lines of evidence suggest that progressive accumulation of the Aβ plays a central role in the genesis of Alzheimers disease and it was long understood that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Aβ fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Aβ fibrils formation and depolymerizate Aβ fibrils also. Over the past decade, data have emerged from the use of several sources of Aβ (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Aβ oligomers are also injurious. Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, β-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Aβ revealed a significant dose-dependent decrease in the levels of cytosolic β-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Aβ, therefore the activation of Wnt signaling protects agains the Aβ neurotoxicity. Here we review recent progress about Aβ structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Aβ oligomers.
Export Options
About this article
Cite this article as:
Cerpa Waldo, Dinamarca C. Margarita and Inestrosa C. Nibaldo, Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses, Current Alzheimer Research 2008; 5 (3) . https://dx.doi.org/10.2174/156720508784533321
DOI https://dx.doi.org/10.2174/156720508784533321 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Current Alzheimer Research Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Effect of Lithium on Neurocognitive Functioning
Current Alzheimer Research Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Current Medicinal Chemistry The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-Review
Current Alzheimer Research Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer’s Disease
Current Neurovascular Research Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Drusen in the Peripheral Retina of the Alzheimer’s Eye
Current Alzheimer Research The Catalytic Core of γ-Secretase: Presenilin Revisited
Current Alzheimer Research Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?
Current Alzheimer Research Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Impacts of Hyper-Homocysteinemia and White Matter Hyper-Intensity in Alzheimers Disease Patients with Normal Creatinine: An MRI-Based Study with Longitudinal Follow-up
Current Alzheimer Research Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry